On the stock market since 2021, it operates in the world of health and science. It has 205 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Revenue is spread across several lines; no single product carries the company.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 95% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 14% a year on average.
Sales run at $81.7M a year. A small number, but proof the product has real buyers.
The average analyst price target is $4.98 — 286% above today’s price.
A loss of $55.4M against $81.7M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
Over the last 12 months, executives reported 71 sells against just 9 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, AKYA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AKYA is a high-risk stock — not yet profitable, and its future rides on its product catching on.